Pharmacological modulation of lipid signaling

Lipids regulate a broad spectrum of cellular functions through spatiotemporally controlled lipid-protein interactions. Dysregulation of lipid metabolism and lipid-mediated signaling is associated with diverse human diseases, including cancer, metabolic disorders, and neurodegenerative conditions. Consequently, selective inhibition of site-specific lipid-protein interactions has emerged as a promising therapeutic strategy to modulate aberrant cell signaling at the membrane interface. Here, we present a streamlined, quantitative workflow for the discovery, characterization, and evaluation of small-molecule inhibitors that disrupt lipid-dependent membrane association and activation of cytosolic signaling proteins. The protocol integrates a high-throughput fluorescence-quenching assay for inhibitor screening, detailed biochemical and cellular target-validation methods, and standardized procedures for in vitro and in vivo assessment of inhibitor potency, specificity, and safety. These general protocols provide a versatile and reproducible platform for developing potent, specific, and mechanistically defined inhibitors targeting a wide range of lipid-binding proteins implicated in disease.